People · Operator
Named in public records as an officer, director or promoter · active 2014–2020 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $65.1M | $1.0B | 2014 |
Justin Klee at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Justin Klee on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter B. Finn | 1 | 11 |
| Isaac Cheng | 1 | 9 |
| Joshua Cohen | 1 | 8 |
| Peter Finn | 1 | 5 |
| Stephen D. Chubb | 1 | 2 |
| STEPHEN CHUBB | 1 | 2 |
| George M. Milne, PH.D. | 1 | 1 |
| George Milne | 1 | 1 |
| Walter Gilbert | 1 | 1 |
| Felix Von Coerper | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.